Post-finasteride syndrome (PFS) is a condition in which sexual, neuropsychiatric, and physical side effects from finasteride persist for months or years after stopping the drug. Finasteride is widely prescribed at 1 mg for male pattern hair loss and at 5 mg for enlarged prostate. Most people tolerate it without lasting problems, but a subset of users develop symptoms that do not resolve when they quit taking it. The condition remains controversial in parts of the medical community, though regulatory agencies in both the US and Europe have progressively strengthened their warnings about persistent adverse effects.
How Finasteride Works in the Body
Finasteride blocks an enzyme called 5-alpha reductase, which converts testosterone into a more potent hormone called DHT. Reducing DHT slows hair loss and shrinks an enlarged prostate. But the same enzyme also produces neurosteroids, chemicals that regulate mood, anxiety, and cognition by acting on calming receptors in the brain. Animal research has shown that finasteride can nearly completely deplete one of these key neurosteroids, allopregnanolone, from the brain at sufficient doses. Allopregnanolone is a potent activator of the brain’s main calming system (GABA-A receptors), which helps explain why some users develop psychiatric symptoms that go beyond what a simple hormonal shift would predict.
Symptoms Across Three Categories
PFS affects three broad domains: sexual function, mental health, and physical wellbeing. The range is wide, and not every person with PFS experiences all of them.
Sexual Symptoms
The most commonly reported problems are decreased or completely absent libido, erectile dysfunction, reduced genital sensitivity, and diminished or absent pleasure during orgasm. Some men also report reduced ejaculatory volume, poor semen quality, and infertility. Less common but documented symptoms include penile shrinkage, abnormal penile curvature (Peyronie’s disease), testicular pain, and testicular shrinkage.
Neuropsychiatric Symptoms
Depression, anxiety, panic attacks, emotional numbness, and insomnia are frequently reported. Memory problems, slow thinking, and difficulty with comprehension also appear in many cases. Suicidal ideation is the most serious psychiatric risk. Between 2017 and 2023, four independent analyses of adverse event reporting systems and four studies using healthcare records all found a significant increase in the risk of depression, anxiety, or suicidal behavior among finasteride users. A 2025 review in the Journal of Clinical Psychiatry estimated that over two decades worldwide, hundreds of thousands of people may have experienced depression from finasteride, and hundreds may have died by suicide.
Physical Symptoms
Chronic fatigue, muscle weakness, muscle wasting or pain, muscle spasms, joint pain, and dry skin round out the physical picture. Some patients also report depersonalization and sensory changes involving skin, smell, taste, or vision. Breast tissue enlargement (gynecomastia) has been documented as well.
How It Gets Diagnosed
There is no blood test or imaging scan that confirms PFS. Diagnosis is clinical, based on a set of criteria published in 2022 that apply to persistent sexual dysfunction caused by finasteride, certain antidepressants, and isotretinoin. The core requirements are straightforward: at least one enduring sexual symptom, such as inability to orgasm or decreased sensation of pleasure during orgasm, that has been present for three or more months after stopping the drug. There should be no evidence that the same sexual dysfunction existed before taking finasteride, no current medical condition that could explain the symptoms, and no other medication or substance use that could account for them.
Ancillary features that support the diagnosis include genital pain, reduced nipple sensitivity, loss of nocturnal erections, reduced ejaculatory force, emotional numbing, depersonalization, cognitive impairment, and other sensory changes. These criteria give clinicians a consistent framework, but many doctors remain unfamiliar with them.
What May Be Happening Biologically
The leading hypothesis involves epigenetic changes, alterations to how genes are expressed without changing the DNA sequence itself. A pilot study comparing cerebrospinal fluid from PFS patients and healthy controls found that the gene responsible for producing the enzyme finasteride blocks (SRD5A2) was silenced by a chemical modification called methylation in 56% of PFS patients, compared to just 8% of controls. This methylation was only found in cerebrospinal fluid, not in blood samples, suggesting the change is tissue-specific and concentrated in the central nervous system. In patients where the methylation was detected, the levels ranged from about 15% to 100%, with a median of roughly 32%.
This finding is significant because it suggests finasteride may, in some individuals, trigger a lasting shutdown of enzyme production in the brain even after the drug is gone. If the enzyme stays silenced, the brain continues to be deprived of the neurosteroids it needs, potentially explaining why symptoms persist indefinitely. This research is still in its early stages with small sample sizes, but it offers the most concrete biological explanation so far.
What Regulators Have Said
Regulatory recognition has been slow but has accelerated in recent years. In 2017, the European Medicines Agency required warnings about mood changes, including depressed mood and suicidal ideation, on finasteride product labels. Anxiety was added to the European label in 2018. In July 2024, the EMA added suicidal ideation as an officially recognized adverse reaction for both Propecia (1 mg) and Proscar (5 mg).
In the United States, the FDA initially stated that a petition from the Post-Finasteride Syndrome Foundation did not provide “reasonable evidence” of a causal link between finasteride and persistent sexual dysfunction, depression, or suicide. However, in August 2022, the FDA required the addition of suicidal ideation and behavior to the listed adverse reactions for finasteride based on reports from patients using the 1 mg hair loss dose.
How Common Is It?
Pinning down a precise incidence rate is difficult because study designs vary widely and the condition lacks a universally applied diagnostic code. The PLESS trial, the largest controlled study of finasteride for enlarged prostate, found that only 50% of finasteride users who developed sexual side effects saw those problems resolve after stopping the drug. Notably, only 41% of the placebo group saw resolution of their sexual side effects, which complicates interpretation. In the Prostate Cancer Prevention Trial, which followed more than 17,000 men, no cases of persistent sexual dysfunction or depression were formally reported, though critics argue the study was not designed to detect them.
On the other end of the spectrum, a 2011 study of 71 men with hair loss who self-reported persistent sexual side effects lasting more than three months after quitting finasteride found that at reassessment, 89% still had sexual dysfunction. This was not a representative population study but rather a group of men who already identified as having a problem, so it speaks more to how persistent the symptoms are once they develop than to how many users are affected overall.
Treatment Options
No established cure for PFS currently exists. Management is largely symptom-based. For erectile dysfunction, PDE5 inhibitors (the class of drugs that includes Viagra) can help some men achieve erections, though they do not address reduced desire or sensation. Some clinicians have reported success using a multifactorial approach that addresses the psychological, relational, and physical dimensions of sexual function simultaneously rather than treating each symptom in isolation.
For psychiatric symptoms like depression and anxiety, standard treatments such as therapy and medication are used, though the irony that some antidepressants (SSRIs) can themselves cause persistent sexual dysfunction makes prescribing more complicated. Hormonal therapies have been tried by some physicians, but results are inconsistent, and no controlled trials support a specific hormonal protocol for PFS. The absence of a clear treatment path is one of the most frustrating aspects of the condition for those living with it.